Policy Notices

• New NIH "FORMS-H" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2023
  (NOT-OD-22-195)
  National Institutes of Health
  Agency for Healthcare Research and Quality
  Food and Drug Administration
  

General Notices

• Notice of Pre-Application Webinar and Frequently Asked Questions (FAQs) for RFA-DK-22-001 Stakeholder Engagement Innovation Center for Advancing Health Equity in Type 2 Diabetes Research (U2C - Clinical Trial Not Allowed)
  (NOT-DK-22-023)
  National Institute of Diabetes and Digestive and Kidney Diseases
  

• Notice of Information: High-Priority Principles of Rigorous Research for NINDS Materials to Enhance Training in Experimental Rigor (METER) Funding Opportunity
  (NOT-NS-23-011)
  National Institute of Neurological Disorders and Stroke
  

• Findings of Research Misconduct
  (NOT-OD-22-197)
  Office of the Director, NIH
  

Notice of Changes to Funding Opportunities

• Notice of Correction to RFA-DA-23-053, "HEAL Initiative: Translating Research to Practice to End the Overdose Crisis (R61/R33 Clinical Trial Optional)"
  (NOT-DA-22-066)
  National Institute on Drug Abuse
  

• Notice of Correction to Eligibility-Related Dates Table in PAR-22-191 "Postdoctoral Research Associate Training (PRAT) Program (Fi2)"
  (NOT-GM-22-043)
  National Institute of General Medical Sciences
  

• Notice of Correction to Key Dates for RFA-NS-22-040 "BRAIN Initiative: Team-Research BRAIN Circuit Programs - TeamBCP (U19 Clinical Trial Not Allowed)"
  (NOT-NS-22-112)
  National Institute of Neurological Disorders and Stroke
  

Funding Opportunities

• AHRQ Mentored Clinical Scientist Research Career Development Award (K08)
  (PA-22-232)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): February 13, 2027
  
  

• NIAMS Clinical Trial Planning Grant (R34) - Clinical Trial Not Allowed
  (PAR-22-205)
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Advancing Research to Understand Congenital Malformations (R01 Clinical Trial Not Allowed)
  (PAR-22-215)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): September 07, 2025
  
  

• AD/ADRD, Adverse Childhood Experiences, and Social Determinants of Health Ancillary Studies of Existing Longitudinal Cohorts (R01 - Clinical Trial Not Allowed)
  (PAR-22-221)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): October 05, 2022
  
  

• Identifying Host Cell Death Pathway Targets for Host-Directed Therapies for Treatment of Mtb and Mtb/HIV Co-Infection (R01 Clinical Trial Not Allowed)
  (PAR-22-223)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): December 07, 2024
  
  

• Building Infrastructure for Precision Medicine Research on Minority Health and Disparities in Alzheimers Disease (AD) and AD-Related Dementias (ADRD) (UH2/UH3 Clinical Trial Not Allowed)
  (RFA-AG-23-020)
  National Institute on Aging
  Application Receipt Date(s): October 21, 2022
  
  

• Allergy and Asthma Statistical and Clinical Coordinating Center (AA-SCCC) (U01 Clinical Trial Not Allowed)
  (RFA-AI-22-054)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): November 30, 2022
  
  

• Transplantation Statistical and Clinical Coordinating Center (T-SCCC) (U01 Clinical Trial Not Allowed)
  (RFA-AI-22-057)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): November 30, 2022
  
  

• National Institute of Allergy and Infectious Diseases (NIAID) Clinical Data and Safety Management Center (CDSMC) (U01 Clinical Trial Not Allowed)
  (RFA-AI-22-058)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): November 30, 2022
  
  

• REsearch Across Complementary and Integrative Health Institutions (REACH) Virtual Resource Centers (U24 Clinical Trial Not Allowed)
  (RFA-AT-23-004)
  National Center for Complementary and Integrative Health
  Application Receipt Date(s): November 10, 2022
  
  

• NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research (R01 Clinical Trial Optional)
  (RFA-DA-23-013)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R01 Clinical Trial Optional)
  (RFA-DA-23-023)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial/Ethnic Populations (R34 Clinical Trial Optional)
  (RFA-DA-23-024)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• NIDA REI: Coordination Center to Support Racial Equity and Substance Use Disparities Research (U24 Clinical Trial Not Allowed)
  (RFA-DA-23-025)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 15, 2022
  
  

• NIDA REI: Racial Equity Visionary Award Program for Research on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
  (RFA-DA-23-026)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• NIDA REI: Research on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
  (RFA-DA-23-028)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• NIDA REI: Research at Minority Serving Institutions on Neurocognitive Mechanisms Underlying the Impact of Structural Racism on the Substance Use Trajectory (R61/R33 Clinical Trial Optional)
  (RFA-DA-23-029)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NIDA REI: Racial Equity Visionary Award Program for Research at Minority Serving Institutions on Substance Use and Racial Equity (DP1 Clinical Trial Optional)
  (RFA-DA-23-031)
  National Institute on Drug Abuse
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• NIDA REI: Addressing Racial Equity in Substance Use and Addiction Outcomes Through Community-Engaged Research at Minority Serving Institutions (R01 Clinical Trial Optional)
  (RFA-DA-23-032)
  National Institute on Drug Abuse
  Application Receipt Date(s): November 14, 2024
  
  

• Reproductive Scientist Development Program (RSDP) (K12 Clinical Trial Not Allowed)
  (RFA-HD-23-012)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): November 30, 2022
  
  

• Connecting Machine Readable Digital Human AD/ADRD Neuropathological Library Platforms for Advanced Analytics (U24 Clinical Trial Not Allowed)
  (RFA-NS-22-062)
  National Institute of Neurological Disorders and Stroke
  National Institute on Aging
  Application Receipt Date(s): November 04, 2022
  
  

• HEAL Initiative: Development and Validation of Non-Rodent Mammalian Models of Pain(R01 Clinical Trial Not Allowed)
  (RFA-NS-22-070)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Cancer Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Diabetes and Digestive and Kidney Diseases
  Application Receipt Date(s): March 06, 2024